Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
The Medical Clinics of North America|December 19, 2003
Patients with inferior vena caval filters should receive chronic thromboprophylaxisMarcelo P V Gomes, Karen L Kaplan, Steven R Deitcher
The Journal of Pediatrics|December 8, 2004
Clinically evident venous thromboembolic events in children with brain tumorsSteven R Deitcher, Amar Gajjar, Larry Kun, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 21, 2013
Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapyLawrence D Kaplan, Steven R Deitcher, Jeffrey A Silverman, et al.
Southern Medical Journal|February 27, 2003
Prevention of thromboembolism after neurosurgery for brain and spinal tumorsTeresa L Carman, Andrew A Kanner, Gene H Barnett, et al.
The Medical Clinics of North America|December 19, 2003
Estrogen-containing oral contraceptives are allowable in young women with factor V Leiden heterozygosity without a history of thrombosisMarie M Budev, Majed Abu-Hajir, Steven R Deitcher, et al.
The Journal of Pediatrics|February 28, 2002
Lepirudin anticoagulation for heparin-induced thrombocytopeniaSteven R Deitcher, Arthur P Topoulos, John R Bartholomew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devicesStephan Moll, Peter Kenyon, Luigi Bertoli, et al.
International Seminars in Surgical Oncology : ISSO|September 6, 2005
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosisGordan Srkalovic, Marte G Cameron, Steven R Deitcher, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 10, 2002
Treatment of occluded central venous catheters with alteplase: results in 1,064 patientsCharles P Semba, Steven R Deitcher, Xin Li, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2006
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodSteven R Deitcher, Craig M Kessler, Geno Merli, et al.
Pageof 5